Barclays PLC Increases Stock Position in Savara Inc (NASDAQ:SVRA)

Barclays PLC boosted its stake in Savara Inc (NASDAQ:SVRA) by 217.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 231,005 shares of the company’s stock after purchasing an additional 158,244 shares during the quarter. Barclays PLC owned about 0.13% of Savara worth $979,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in shares of Savara by 9.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after buying an additional 3,706 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after buying an additional 6,141 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares in the last quarter. ClariVest Asset Management LLC raised its position in shares of Savara by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company’s stock valued at $1,034,000 after buying an additional 7,170 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Savara by 7.0% during the 3rd quarter. Victory Capital Management Inc. now owns 140,010 shares of the company’s stock valued at $594,000 after purchasing an additional 9,180 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SVRA. HC Wainwright cut their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Evercore ISI reiterated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th. Finally, Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.86.

Savara Trading Down 2.2 %

NASDAQ:SVRA opened at $3.08 on Tuesday. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70. The firm has a fifty day simple moving average of $3.41 and a 200-day simple moving average of $3.95. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $528.59 million, a P/E ratio of -7.16 and a beta of 0.92.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). On average, equities research analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Insider Activity at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph S. Mccracken acquired 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.